EudraVigilance NEU. Mag. pharm. Katharina Weber. BASG/AGES Medizinmarktaufsicht Institut Überwachung - Abteilung Blut, Gewebe und Vigilanz
|
|
- Barnard Lawrence
- 6 years ago
- Views:
Transcription
1 EudraVigilance NEU Mag. pharm. Katharina Weber BASG/AGES Medizinmarktaufsicht Institut Überwachung - Abteilung Blut, Gewebe und Vigilanz
2 AGENDA EudraVigilance neu Legal Requirements Process Change Management EV System Implementation plan Stakeholder Implementation planning Addressed questions: Reporting of medication errors Reporting of off-label-use Reporting of issues in combination with medical devices PV Inspections Supporting Information 2
3 EudraVigilance neu Management Board endorsement starts countdown for stakeholders to get ready for launch of improved system in November 2017 The new version of EudraVigilance will go live on 22 November 2017 with enhanced functionalities for reporting and analysing suspected adverse reactions jsp&mid=WC0b01ac058004d5c1 3
4 Legal Requirements Regulation (EC) No 726/2004 (amended 1235/2010) Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency Directive 2001/83/EC (amended 2010/84/EU) Community code relating to medicinal products for human use Implementing Regulation (EU) No 520/2012 on the performance of pharmacovigilance activities provided for in Regulation (EC) No 726/2004 of the European Parliament and of the Council and Directive 2001/83/EC of the European Parliament and of the Council 4
5 Legal Requirements The main changes to electronic reporting requirements are: Usage of ISO standards in the reporting of ICSRs, ISO ICSR standard :2011 Usage of ISO IDMP terminologies, once available, in the submission of ISO ICSR messages EMA medical literature monitoring service The audit of the EudraVigilance system Simplification of reporting of ICSRs in the EU and forwarding of national cases to the relevant NCA. 5
6 Process Change Management 6
7 Process Change Management EudraVigilance 8 7
8 Process Change Management Submission von ICSRs within EEA MAH Procedure Origin Adverse reaction type Destination Time frame Centralised Mutual recogintion, decentralised or subject to referral purely national EU All serious Eudravigilance Database 15 days All non serious Eudravigilance Database 90 days Non EU All serious Eudravigilance Database 15 days Note: in E2B(R3), seriousness is reported at event level rather than at case level in E2B(R2) => if any event is considered serious then the whole case should be considered serious. 8
9 Process Change Management Clinical trial SUSAR reporting Until the clinical trials regulation is applicable there is no change to the current process for the submission of SUSARs for clinical trials. EEA case submissions to the WHO UMC Following the implementation of the new EudraVigilance system, ICSR submissions for cases occurring in the EEA should only be made by the EudraVigilance system to WHO-UMC. 9
10 Process Change Management Signal Management Authorised users of the EudraVigilance Data Analysis System (EVDAS) will be expected to retrieve data and use the available predefined reports included in the newly implemented functionalities in order to meet their data analysis and signal detection obligations. User Manual and training materials Revised EudraVigilance Access Policy Revised GVP Module IX (planned approval by PRAC in 07/2017 coming into force in 11/2017) Module IX Addendum I Methodological Aspects of Signal Detection from Spontaneous Reports of Suspected Adverse Reactions (planned approval by PRAC in 07/
11 Process Change Management Signal Management Definition according to the Council for International Organisations of Medical Sciences WG VIII : Information that arises from one or multiple sources (including observations and experiments), which suggests a new potentially causal association, or a new aspect of a known association, between an intervention and an event or set of related events, either adverse (or beneficial), that is judged to be of sufficient likelihood to justify verificatory action. Performance of signal detection activities required by the EU pharmacovigilance legislation* *COMMISSION IMPLEMENTING REGULATION (EU) No 520/2012 of 19 June 2012 on the performance of pharmacovigilance activities provided for in Regulation (EC) No 726/2004 of the European Parliament and of the Council and Directive 2001/83/EC of the European Parliament and of the Council 11
12 Process Change Management Exchange of information MAH, NCAs, EMA PRAC Rapp, Lead MS PRAC Detection Validation Confirmation Analysis & prioritisation (PRAC) Assessment (Lead-NCA, PRAC Rapp) Recomm. for action (PRAC) MAH: additional data MAH: Act upon PRAC recomm. 12
13 Process Change Management 1. Signal Detection Identifying signals using data from any source (MAH, EudraVigilance, national ADRdatabases, non-eu regulatory agencies, combination of statistical methods and review of ICSRs and scientific literature) 2. Signal Validation Process of evaluating in order to verify that the available documentation contains sufficient evidence demonstrating the existence of a new potentially causal association or a new aspect of a known association (Justification for further analysis, incl. clinical significance of the signal, its previous awareness, the biological and temporal plausibility and any relevant sources of information) EMA and NCA EPITT* MAH Emerging Safety Issue * European Pharmacovigilance Information Tracking Tool 13
14 Process Change Management VI.C Emerging safety issues Events may occur, which do not fall within the definition of reportable valid ICSRs, and thus are not subject to the reporting requirements, even though they may lead to changes in the known riskbenefit balance of a medicinal product and/or impact on public health. major safety findings from a newly completed non-clinical study; major safety concerns identified in the course of a non-interventional post-authorisation study or of a clinical trial; signal of a possible teratogen effect or of significant hazard to public health; safety issues published in the scientific and medical literature; safety issues arising from the signal detection activity (see Module IX) or emerging from a new ICSR and which impact on the risk-benefit balance of the medicinal product and/or have implications for public health; safety issues related to the use outside the terms of the marketing authorisation; safety issues due to misinformation in the product information; marketing authorisation withdrawal, non-renewal, revocation or suspension outside the EU for safety-related reasons; urgent safety restrictions outside the EU; safety issues in relation to the supply of raw material; lack of supply of medicines. 14
15 Process Change Management VI.C Emerging safety issues / Signal Validation These events/observations, which may affect the risk-benefit balance of a medicinal product should be notified as emerging safety issues in writing to the competent authorities in Member States where the medicinal product is authorised and to the Agency via (P-PV-emerging-safety-issue@ema.europa.eu); This should be done immediately when becoming aware of them. MAHs should provide a precise description of the safety issue, including the available evidence and the proposed regulatory action(s). All other validated signals should be handled according to available guidelines (see Module IX Signal management of the GVP) Validated signals should also be presented in the relevant sections of the periodic safety update report (PSUR) (see also Module VII - Periodic safety update report (Rev 1) of the GVP). 15
16 Process Change Management 3. Signal Confirmation Communication via EPITT, within 30 days of its receipt by the Rapporteur, the lead Member State or a national competent authority that the validated signal is confirmed or not confirmed. Any confirmed signal should be analysed and prioritised by the Pharmacovigilance Risk Assessment Committee (PRAC). 4. Signal Analysis and Priorisation Prepared by the confirmer, for endorsement by the PRAC; taking into account the potential impact of the signal on the benefit-risk profile of the involved medicine(s); 5. Signal Assessment scientific evaluation of all the evidence available, including additional data from MAHs; responsibility of the PRAC. At the start of an evaluation, the PRAC appoints a Rapporteur who takes the lead for the assessment of all collected data. 16
17 Process Change Management 6. Recommendation for action Responsibility of the PRAC possible actions are: no need for further evaluation or action at this point of time; need for additional information: the MAH, Member States and/or the EMA, where relevant, should monitor any relevant emerging information on the signal as it becomes available; the MAH should address the signal in the following PSUR or submit an ad-hoc PSUR; the MAH should submit additional data; the EMA or Member States, as relevant, should collect further information (e.g. via a nonurgent information request) or perform additional analyses in EudraVigilance or other data sources; the MAH(s) should conduct a post-authorisation safety study; need for regulatory action: the product information and/or risk management plan (RMP) should be updated through a variation; the Member States or the Commission, as appropriate, should initiate a referral procedure; urgent safety restrictions should be imposed. These actions may be accompanied by additional communication measures, e.g. a Direct Healthcare Professional Communication (DHPC). pharmacovigilance inspection should take place. 17
18 Process Change Management 6. Recommendation for action Responsibility of the PRAC When applicable the PRAC recommendation includes the timeline for the action(s) and a brief rationale. PRAC recommendations to provide additional data are directly actionable by the concerned MAHs. PRAC recommendations for regulatory action are submitted to the Committee for Medicinal Products for Human Use (CHMP), in case of CAPs inclusion, and to the Coordination group for Mutual recognition and Decentralised procedures human (CMDh) for information in the case of NAPs, before implementation by the concerned MAHs. All PRAC recommendations on signals are published on the EMA website within a month of the relevant PRAC meeting and are further reflected in the meeting minutes. 18
19 Process Change Management Signal Management place for improvement Criteria for quality management Description of the whole process (detection / validation / communication to NCAs / implementation of recommendation) Method of signal detection (sources, statistics incl. algorithm and rationale) Frequency of signal detection (risk based approach) Method of causality assessment and outcome Communication to NCAs and EMA Qualified staff (trainings, documentation of courses) standardised documentation of all steps (incl. tracking) Regular audits 19
20 EV System Implementation plan EV System Implementation plan EV system is being updated to be ISO ICSR :2011 (E2B(R3)) compliant Before the move to simplified reporting, the new EudraVigilance system has to undergo an independent audit that will check that the required functionalities. several changes in EudraVigilance: adapting the EudraVigilance Gateway, the secure electronic communication tool to exchange ICSRs, to accept ICH E2B(R2) as well as (R3) files; adapting the EudraVigilance database management system (EDBMS) to support the storage and processing of reports submitted with the new ICH ICSR format migrating all existing ICH E2B(R2) ICSR data to the new ICH ICSR format; redesign of EVWEB, the web application for the electronic reporting and management of ICSRs in the ISO ICSR format, using a new technology; introducing new functionalities in the EudraVigilance data analysis system (EVDAS), including the adrreports.eu portal, to support analysis of data and support signal management activities In addition, EMA will add the following two new functionalities to the system: EudraVigilance rerouting functionality, which defines the rules for the forwarding of ICSRs to the national competent authority (NCA) where the adverse reaction occurred (rules can be set by NCAs according to their needs and preferences); ICSR download functionality to enable marketing authorisation holders to download ICSRs concerning their products or ICSRs reported with a substance for which they hold a marketing authorisation in the EEA. 20
21 EV System Implementation plan EV System Implementation plan 21
22 EV System Implementation plan EV database management system The EudraVigilance database management system will have the most significant changes as the database will be updated to support the E2B(R3) structure and fields. All existing E2B(R2) data will be migrated into this new database. The XML parser2 will be replaced and will be able to process both E2B(R2) and E2B(R3) messages. If an E2B(R2) message is sent to the EudraVigilance system, an E2B(R2) acknowledgement message will be returned. Likewise, an E2B(R3) acknowledgment will be returned for E2B(R3) ICSR messages. EudraVigilance applications for Medicinal Product Recoding and Duplicate Detection and management will also be amended to support E2B(R3). Master cases that are produced by the EMA in response to identifying duplicated ICSR in the EudraVigilance system will be produced in E2B(R3) format only. 22
23 EV System Implementation plan EV data analysis system (EVDAS): The EudraVigilance data analysis system (EVDAS) will be updated to the new E2B(R3) data structure. a) Healthcare professionals and general public The current European database of suspected adverse drug reaction reports ( ) will be updated and improved to include: Weekly refresh of published data; Publication of data for non-serious cases received in EudraVigilance; Publication of country data (in aggregated dashboard); Publication of additional data elements via Line listing reports and the new ICSR form (replacing the existing CIOMS I form). b) Marketing Authorisation Holders (for Signal detection) The electronic Reaction Monitoring Report (ermr) based on the ermr used within the EU network and the EMA for signal detection activities; The individual case line listing and ICSR form. 23
24 EV System Implementation plan ICSR download function for MAHs After the switch to simplified reporting, MAHs will no longer receive ICSRs directly from NCAs. In order for MAHs to receive ICSRs concerning their products download functionality will be made available. It should be noted that the ICSRs that will be provided via this download functionality will only be available in E2B(R3) format. The download function will be made available through the new EVWEB application. 24
25 EV System Implementation plan Testing with the new EudraVigilance system and user training Once the Audit has been completed, all organisations with a registered Test EudraVigilance account can start sending E2B(R3) Test files and will also be able to download E2B(R3) files based on test data. In addition, EVWEB users will be able to view and use the new EVWEB interface in the Test EudraVigilance system. The EMA will publish a user guide, online elearning, training materials and provide support webinars. The training materials will explain the new E2B(R3) format including the new data fields and the new EVWEB tool. 25
26 Stakeholder Implementation planning MAH Change Management Summary 26
27 Stakeholder Implementation planning MAH Change Management Summary 27
28 Stakeholder Implementation planning The EudraVigilance helpdesk: EudraVigilance Registration - eudravigilanceregistration@ema.europa.eu EMA IT Service Desk Link - (For support with EudraVigilance and EMA gateway/webclient) 28
29 AGENDA EudraVigilance neu Legal Requirements Process Change Management EV System Implementation plan Stakeholder Implementation planning addressed questions: Reporting of medication errors Reporting of off-label-use Reporting of issues in combination with medical devices PV Inspections Supporting Information 29
30 Reporting of medication errors A medication error is an unintended failure in the drug treatment process that leads to, or has the potential to lead to, harm to the patient. To be reported in the E2B field reaction E2B(R2): B.2.i.1.b = E2B(R3): E.i.2.1 only if really reported as medication error by primary source; otherwise as Sender s diagnosis in E2B(R2)- field B.5.3.b = E2B(R3): H.3.r.1.b 30
31 Reporting of medication errors Suspected (serious and non-serious) adverse reactions associated with medication errors should be recorded, reported and assessed. Should be reported as Emerging Safety Issue if important safety concern which impacts on the overall benefit-risk balance of the medicinal product involved or on public health 31
32 Reporting of medication errors NO adverse reaction => only in PSUR summary and RMP 32
33 Reporting of medication errors 33
34 Reporting of off-label-use GVP Module VI.A b. Off-label use This relates to situations where the medicinal product is intentionally used for a medical purpose not in accordance with the authorised product information. VI.B.6.3. : Reports of overdose, abuse, off-label use, misuse, medication error or occupational exposure with no associated adverse reaction should not be reported as ICSRs. They should be considered in periodic safety update reports as applicable. Reports associated with suspected adverse reactions => reported as ICSR 34
35 Reporting of Issues in Comb. with MD Medizinproduktegesetz: Abgrenzung zu Arzneimittelregelungen 5. (1) Medizinprodukte, die im Zeitpunkt der Abgabe kein Arzneimittel enthalten, jedoch dazu bestimmt sind, ein Arzneimittel im Sinne des Arzneimittelgesetzes anzuwenden, unterliegen diesem Bundesgesetz unbeschadet der das Arzneimittel betreffenden Bestimmungen des Arzneimittelgesetzes. (2) Wird eine Kombination von Medizinprodukt und Arzneimittel so in Verkehr gebracht, dass Medizinprodukt und Arzneimittel ein einheitliches, miteinander verbundenes Produkt bilden, dessen bestimmungsgemäße Hauptwirkung auf der stofflichen Zusammensetzung des Arzneimittels beruht und das ausschließlich zur Verwendung in dieser Verbindung bestimmt und nicht wiederverwendbar ist, so unterliegt dieses Produkt dem Arzneimittelgesetz. 35
36 PV - Inspections PV-Systeminspections: Inspection of the PV - Documentation (the complete PV-System) Risked based Inspection-planning (also in accordance with other Agencies) Approx. Duration: 1,5 2 d PV/GMP-Inspectionens Processed in accordance with GMP-INS Procedure (PV-Inspection will be mentioned in GMP- Inspection - Announcement) Screening of the national PV- scenery preferred for SME Approx. Duration: 0,5 1 d 36
37 PV - Inspections PV - Inspectionsprogramm in AT Main Focus: MAH with PSMF (QPPV) in AT Inspection of concerned MAHs (risk-based approach: Inspection-Status, PSMF-Status, and Compliance-Information) After the first Inspection: Definition of Inspection-intervall enhanced Programm: MAH as locale Affiliate Inspection of all concerned MAHs (risk-based approach : product types, internal/external triggers, as well as other EU PV INS activities) After the first Inspection: Definition of Inspection-intervall (risk-based) 37
38 Supporting Information - 01 EV Change Management: _and_a/q_and_a_detail_ jsp (EudraVigilance Change Management) ory_and_procedural_guideline/2015/10/wc pdf (revised EudraVigilance Stakeholder Change Management Plan) ory_and_procedural_guideline/2016/04/wc pdf (EudraVigilance auditable requirement project - EudraVigilance training plan ) 015/12/WC pdf (European Medicines Agency policy on access to EudraVigilance data for medicinal products for human use (EudraVigilance Access Policy)) 013/09/WC pdf (Questions & answers on signal management) 38
39 Supporting Information - 02 EV Change Management: WC pdf (Safety Signal - Assessment of responses to Request for Supplementary Information (RSI)) nt_listing/document_listing_ jsp (PRAC recommendations on safety signals) q_and_a_detail_ jsp&mid=wc0b01ac0580a68f78 (EudraVigilance system overview) (ISO ICSR standard / ICH E2B(R3) ) ews/2015/01/news_detail_ jsp&mid=wc0b01ac058004d5c1 (New international standard to improve safety of medicines) 39
40 Supporting Information _procedural_guideline/2014/04/wc pdf (EU Individual Case Safety Report (ICSR) Implementation Guide ) Medication error: ral/general_content_ jsp (Medication errors) _procedural_guideline/2015/11/wc pdf (Good practice guide on recording, coding, reporting and assessment of medication errors) _procedural_guideline/2015/11/wc pdf (Good practice guide on risk minimisation and prevention of medication errors) Medizinproduktegesetz: Gesetzesnummer=
41 Mag.pharm. Katharina Weber Gutachterin / Inspektorin Pharmakovigilanz BASG - Bundesamt für Sicherheit im Gesundheitswesen Traisengasse Wien katharina.weber@ages.at
New EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change
New EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change Training Module PhV-M1 Overview of legal provisions that form the basis for the new EudraVigilance functionalities
More informationMircea Ciuca, MD Global Head Medical & Clinical Drug Safety
Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety Disclaimer The views and opinions expressed in this presentation are solely those of the presenter and do not necessarily reflect those of Vifor,
More informationEudraVigilance auditable requirement project
22 November 2017 EMA/835422/2016 Information Management Division EudraVigilance training plan (version 5) Project Maintenance Group 1 consultation 11 December 2015 Eudravigilance Expert Working Group consultation
More informationEudraVigilance: Preparing for Change
EudraVigilance: Preparing for Change EudraVigilance Auditable Requirement project 6 th Industry Stakeholder Platform Meeting, 18 th December 2015 Presented by Francois Domergue, Data Standardisation and
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/827661/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module IX Signal management (Rev 1) Date of coming into effect of first version 2 July 2012 Draft Revision 1* finalised
More informationUpdate on preparation for Signal Management
Update on preparation for Signal Management 7 th industry stakeholder platform operation of EU PV legislation Presented by Georgy Genov on 4 April 2016 Head of Signal Management - Pharmacovigilance Department
More informationPharmacovigilance information for pharmaceutical companies
Pharmacovigilance information for pharmaceutical companies Electronic transmission of individual case safety reports (ICSRs) with ANSM (French National Agency for the safety of Medicines and Health Products)
More informationNew pharmacovigilance systems and services
New pharmacovigilance systems and services 17 September 2015, PCWP/HCPWP joint meeting Presented by Peter Arlett, Head of Pharmacovigilance department An agency of the European Union Background The new
More informationPharmacovigilance information for pharmaceutical companies
Pharmacovigilance information for pharmaceutical companies Electronic transmission of individual case safety reports (ICSRs) with ANSM (French National Agency for the safety of Medicines and Health Products)
More informationPharmacovigilance System Master file
IMPLEMENTING MEASURES IN ORDER TO HARMONISE THE PERFORMANCE OF THE PHARMACOVIGILANCE ACTIVITIES PROVIDED FOR IN DIRECTIVE 2001/83/EC AND REGULATION (EC) NO 726/2004 Pharmacovigilance System Master file
More informationUpdate ICSR Reporting. EudraVigilance Reporting Getting ready for E2B (R3) Disclaimer:
Update ICSR Reporting Dr. Waltraud Trabe / Mag. Katharina Weber Austrian Federal Office forsafety in Healthcare Institute of Surveillance Dep. BTVI (Blood, Tissue & Vigilance) Traisengasse5, 1020 Vienna
More informationFeedback on EudraVigilance & new functionalities
Feedback on EudraVigilance & new functionalities 14th industry stakeholder platform operation of EU pharmacovigilance Anja van Haren (MEB), Sabine Brosch (EMA) and Francois Domergue (EMA) An agency of
More informationE2B, Safety databases & Eudravigilance
E2B, Safety databases & Eudravigilance Delphine BERTRAM, PharmD Hospices Civils de Lyon France HOT TOPICS IN PV Hod Hasharon 7 May 2014 Dr Irene Fermont- ISOP ISRAEL Dganit Even Sapir -MSD Spontaneous
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/827661/2011 (superseded version) Guideline on good pharmacovigilance practices (GVP) Module IX Signal management Draft finalised by the Agency in collaboration with Member States and submitted
More informationOverview of the new pharmacovigilance legislation
Overview of the new pharmacovigilance legislation SME workshop: 19 April 2012 Dr Peter Arlett Head, Pharmacovigilance and Risk Management EMA An agency of the European Union In this talk: New legislation
More informationGood Vigilance Practice Module VI
Good Vigilance Practice Module VI Management and reporting of adverse reactions to medicinal products Stakeholders forum 27th February 2012 Gilles Touraille Signal Detection and Data Analysis Pharmacovigilance
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 9 October 2017 EMA/827661/2011 Rev 1* - Track-change version following public consultation 3 4 Guideline on good pharmacovigilance practices (GVP) Module IX Signal management (Rev 1) Date of coming
More informationGVP Module IX: Signal Management
27 February 2012 4 th Stakeholders Forum Presented by: Agnieszka Szmigiel Pharmacovigilance and Risk Management Sector, EMA An agency of the European Union Topics Scope of Module IX Signal Management (SM)
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and
More informationSignal Management in the EU and future extended access to EudraVigilance for industry
Signal Management in the EU and future extended access to EudraVigilance for industry 6 th Industry Stakeholder Platform Meeting, 18 th December 2015 Presented by Georgy Genov 7 December 2015 Head of Signal
More informationImplementing the New Pharmacovigilance Legislation
Implementing the New Pharmacovigilance Legislation Irish Medicines Board, Pharmacovigilance Information Day, Dec 2011 Dr. Almath Spooner Vigilance Assessment Manager, Human Products Monitoring Department
More informationExplanatory Note to GVP Module VII
31 October 2017 EMA/670256/2017 Human Medicines Evaluation Division Explanatory Note to GVP Module VII Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA), the procedure
More informationGuide for Marketing Authorisation Holders on Direct Healthcare Professional Communications
Guide for Marketing Authorisation Holders on Direct Healthcare Professional Communications 1 INTRODUCTION A Direct Healthcare Professional Communication (DHPC) aims to promote safe and effective use of
More informationEudraVigilance stakeholder change management plan: integration with the Identity and Access Management (IAM2) project deliverables
24 May 2018 EMA/349760/2018 Information Management Division EudraVigilance stakeholder change management plan: integration with the Identity and Access Management (IAM2) project deliverables Pharmacovigilance
More informationStakeholder Meeting, 17 June 2011, EMA, London. Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency
New Pharmacovigilance Legislation and Implementing Measures Minimum Requirements for Quality Systems (MAH, EMA, NCA), minimum requirements for Pharmacovigilance System Master File Stakeholder Meeting,
More informationPharmacovigilance: Information systems and Services
Pharmacovigilance: Information systems and Services 3 rd Industry stakeholder platform operation of EU Pharmacovigilance legislation Presented by Peter Arlett Head of Pharmacovigilance Department An agency
More informationFunctioning of the PRAC
Functioning of the PRAC Sixth Stakeholders forum on the implementation of the new Pharmacovigilance legislation, November 8 th 2012 Presented by: Almath Spooner Vice Chair, Pharmacovigilance Risk Assessment
More informationEudraVigilance auditable requirement project: ADRreports.eu portal update
EudraVigilance auditable requirement project: ADRreports.eu portal update Patients and Consumers Working Party 30 th November 2016 Francois Domergue, Business project manager An agency of the European
More informationGuidelines on good pharmacovigilance practices (GVP)
15 September 2014 EMA/475236/2014 Guidelines on good pharmacovigilance practices (GVP) Introductory cover note, last updated with revision 1 of module III on pharmacovigilance inspections and of module
More informationQuality Management in PV. Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017
Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017 - Pharmacovigilance System - Overall Quality objectives in PV - Quality Management System overview - Quality Management System requirements - Quality
More informationRecent developments in Pharmacovigilance from the Regulator s Perspective. In strategy, competence, quality and flexibility
Recent developments in Pharmacovigilance from the Regulator s Perspective In strategy, competence, quality and flexibility Pharmacovigilance Regulatory Affairs Operations Medical Writing & toxicology Recent
More informationWissenswertes aus dem Bereich PHV
Wissenswertes aus dem Bereich PHV Dr. Susanne Wolf Dept. Assessment Pharmacovigilance AGES-Gespräche Vienna, 15.09.2016 Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH www.ages.at
More informationPharmacovigilance. Training session for patients and consumers involved in EMA activities, 25 November Presented by: Priya Bahri
Pharmacovigilance Training session for patients and consumers involved in EMA activities, 25 November 2014 Presented by: Priya Bahri An agency of the European Union 2 Pharmacovigilance - the science concerned
More informationGuidelines for Pharmacovigilance Inspections
PHARMACY BOARD OF SIERRA LEONE Guidelines for Pharmacovigilance Inspections Guideline No. : PBSL/PVGCT/GDL/QPPV/04-2017 Effective Date. :27 th March, 2017 Version No. : 01 1 TABLE OF CONTENT TABLE OF CONTENT
More informationEU Pharmacovigilance Legislation - One Year Later. Sarah Daniels; Senior Partner TranScrip Partners LLP
EU Pharmacovigilance Legislation - One Year Later Sarah Daniels; Senior Partner TranScrip Partners LLP Since July 2012 we have officially been operating under EU legislation Directive 2010/84/EU amending
More informationUK Standards for Pharmacovigilance Departments 2015
UK Standards for Pharmacovigilance Departments 2015 03 UK Standards for Pharmacovigilance Departments 2015 Introduction 1 European legislation (Directive 2010/84/EU; Regulation (EU) No 1235/2010) requires
More informationThe new EudraVigilance System Public Communications Plan for EMA and National Competent Authorities in the EEA
22 November 2017 /413091/2017 The new EudraVigilance System Public Communications Plan for and National Competent Authorities in the EEA An overview of the planned public communication milestones 30 Churchill
More informationGuidelines on good pharmacovigilance practices (GVP)
7 June 2013 EMA/321625/2013 Patient Health Protection Guidelines on good pharmacovigilance practices (GVP) Introductory cover note, last updated with launch of public consultation of module VI revision
More informationFOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS
FOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS Document No. : FDA/SMC/SMD/GL-PVI/2013/02 Date of First Adoption : 1 st February, 2013 Date of Issue : 1 st March, 2013
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/813938/2011 Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies Draft finalised by the Agency in collaboration with Member States and submitted
More informationEMA Comments on Implementing Measures for Pharmacovigilance (PCIM/11/01)
7 November 2011 EMA/863255/2011 EMA Comments on Implementing for Pharmacovigilance (PCIM/11/01) The Agency welcomes the public consultation on the Commission concept paper on the implementing measures
More informationEudraVigilance access policy for medicines for human use
23 August 2011 EMA/759287/2009 corr. Patient Health Protection Draft agreed by the EudraVigilance Expert Working Group December 2007 Consultation with the EudraVigilance Steering Committee February 2008
More informationPROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP. Ad Hoc PhV Inspectors Working Group
European Medicines Agency Inspections London, 20 April 2009 EMEA/INS/PhV/85058/2008 Procedure no: INS/PhV-V/2 PROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP Ad Hoc PhV Inspectors
More informationGuidelines on good pharmacovigilance practices (GVP)
12 April 2013 EMA/131811/2013 Patient Health Protection Guidelines on good pharmacovigilance practices (GVP) Introductory cover note, last updated with revision of module II, launch of public consultation
More informationENCePP Plenary: New Pharmacovigilance legislation
ENCePP Plenary: New Pharmacovigilance legislation 18 November 2010 Peter Arlett Head of Pharmacovigilance and Risk Management EMA An agency of the European Union In this talk 1. New pharmacovigilance legislation:
More informationGVP Module X - additional monitoring of medicines
GVP Module X - additional monitoring of medicines 6 th Stakeholders forum on the implementation of the new pharmacovigilance legislation Mick Foy, Group Manager - MHRA An agency of the European Union Contents
More informationImplementation and Impact of the PV Regulations - how are we doing? Sue Rees Eisai Europe Ltd. & John Barber, Dr Reddy's Laboratories
Implementation and Impact of the PV Regulations - how are we doing? Sue Rees Eisai Europe Ltd. & John Barber, Dr Reddy's Laboratories Agenda PSMF PSURs Solicited sources RMPs Inspections Signal detection
More informationIntroductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update Reports
24 October 2016 EMA/606369/2012 Rev.15 Procedure Management and Committees Support Introductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update
More informationConsultation item no. 1 Should additional processes and pharmacovigilance tasks be covered? No, to our mind the list is complete.
Association Européenne des Spécialités Pharmaceutiques Grand Public Association of the European Self-Medication Industry Europäischer Verband der Arzneimittel-Hersteller AESGP Position Paper on the European
More informationINTRODUCTION OF FEES TO BE CHARGED BY THE EMA FOR PHARMACOVIGILANCE
Ref. Ares(2012)723154-18/06/2012 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Brussels, D(2012) INTRODUCTION OF FEES TO
More informationWhat is an ideal PSUR? A new focus based on aligned expectations
What is an ideal PSUR? A new focus based on aligned expectations Margarida Guimarães PRAC Member INFARMED, I.P. Periodic Safety Update Report Information Day 28 October 2016 London, UK Disclaimer The views
More informationSafety Measures in the new Pharmacovigilance System
Safety Measures in the new Pharmacovigilance System Dr. Harald Tietz Director Global Patient Safety & Regulatory Affairs, Germany Lilly Deutschland GmbH Documentation and reporting requirements: Centralisation
More informationQ & A on PSUSA: Guidance document for assessors
31 October 2017 EMA/518909/2016 Human Medicines Evaluation Division Q & A on PSUSA: Guidance document for assessors Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA),
More informationModule VIII- Post-authorisation safety studies
Good Vigilance Practice Module VIII- Post-authorisation safety studies 4th Stakeholder Forum Xavier Kurz An agency of the European Union Post-authorisation safety study Any study relating to an authorised
More informationPharmacovigilance: Information systems and services
Pharmacovigilance: Information systems and services Supporting business activities of the revised pharmacovigilance legislation through better information systems An agency of the European Union To deliver
More informationQ&A - Pharmacovigilance Legislation
CMDh/257/2012, Rev.18 July 2017 Regulation (EU) No 1235/2010 and Directive 2010/84/EU Table of contents 1. a. As of 21 July 2012, new requirements for marketing authorisation applications have been introduced
More informationPharmacovigilance- Content of the New EU Legislation and Challenges for BfArM
Pharmacovigilance- Content of the New EU Legislation and Challenges for BfArM 12 th DGRA Annual Congress June 15 to 16, Bonn U. Hagemann Bundesinstitut für Arzneimittel und Medizinprodukte BfArM Visit
More informationCMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures
October 2017 CMDh/004/2005/Rev.15 CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Table of contents (optional) 1. Introduction... 2 2. Legal framework...
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/816573/2011 Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file Draft finalised by the Agency in collaboration with Member States and submitted
More informationPSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector
PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector Content Answer industry questions related to the PSMF MHRA inspector s preparation: How we
More informationRegulatory Aspects of Pharmacovigilance
Regulatory Aspects of Pharmacovigilance Deirdre Mc Carthy Pia Caduff-Janosa Training Course Uppsala 2012 Agenda Risk based approach to spontaneous reporting (incl clinical trials) -> Pia Caduff-Janosa
More informationThe Pharmacovigilance Quality System. What is it?
The Pharmacovigilance Quality System What is it? by Andy Blackman 12 November 2018 Are you starting to plan your first Marketing Authorisation Application? If yes, now is the time to start developing your
More informationCMDh STANDARD OPERATING PROCEDURE ON THE PROCESSING OF PSUR SINGLE ASSESSMENT PROCEDURES FOR NATIONALLY AUTHORISED PRODUCTS
CMDh STANDARD OPERATING PROCEDURE ON THE PROCESSING OF PSUR SINGLE ASSESSMENT PROCEDURES FOR NATIONALLY AUTHORISED PRODUCTS 1. INTRODUCTION CMDh/322/2014/Rev.0 November 2014 This Standard Operating Procedure
More informationMarketing Authorisation Routes in the EU
Marketing Authorisation Routes in the EU The EU medicines regulatory system and the European Medicines Agency: an introduction for international regulators and non-governmental organisations 18 September
More informationEMA pharmacovigilance system manual
13 October 2016 EMA/623550/2013 Inspections, Human Medicines Pharmacovigilance & Committees Division Version 1.2 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000
More informationThe European Commission's Proposal to Re-design Existing European Drug Safety Rules. An Industry View on Practical Implications
The European Commission's Proposal to Re-design Existing European Drug Safety Rules An Industry View on Practical Implications Margaret Walters Merck, Sharp & Dohme Ltd. The Second International Pharmaceutical
More informationAdjusting to Effectively Meet the New European Union Pharmacovigilance Requirements
Adjusting to Effectively Meet the New European Union Pharmacovigilance Requirements Deirdre McCarthy Michelle Bulliard GRP Webinar 31 January 2013 Copyright 2013 Quintiles Your Presenters Deirdre McCarthy
More informationFormat and content of electronic periodic safety update reports (Technical contribution to EC implementing measure)
Format and content of electronic periodic safety update reports (Technical contribution to EC implementing measure) First Stakeholders Forum on the implementation of the new Pharmacovigilance legislation,
More informationConcept paper submitted for public consultation. SANCO/D3/FS/cg/ddg1.d.3(2011)
07 Nov 2011 Comments on: Implementing measures in order to harmonise the performance of the pharmacovigilance activities provided for in Directive 2001/83/EC and Regulation (EC) No 726/2004 Concept paper
More informationGuideline on the processing of renewals in the centralised procedure
22 June 2012 EMEA/CHMP/2990/00 Rev.4 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation
More informationGuideline on the processing of renewals in the centralised procedure
22 June 2012 EMEA/CHMP/2990/00 Rev.4 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation
More informationPharmacovigilance. An agency of the European Union
Pharmacovigilance An agency of the European Union Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse reactions and other medicine-related
More informationCTFG 10 September 2010
CTFG 10 September 2010 Clinical Trial Facilitation Group CTFG comments on the European Commission public consultation document CT3: draft detailed guidance on the collection, verification and presentation
More informationNew Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012
New Pharmacovigilance legislation Post-authorisation safety studies ENCePP Plenary meeting 3 May 2012 Presented by: Annalisa Rubino, PhV and Risk Management, EMA An agency of the European Union Why? Public
More informationII.B.4. Information to be contained in the PSMF/ PSSF
II.B.4. Information to be contained in the PSMF/ PSSF No. PSMF/ PSSF section Remarks Cover Page: 1- The unique number (Revision No.) 2- The name of the MAH, QPPV or LSR (including third party). 3- The
More informationChapter 28 Pharmaceutical acquis (human and veterinary medicinal products)
Chapter 28 Pharmaceutical acquis (human and veterinary medicinal products) Screening meeting with Serbia 5 December 2014 DG SANTE D5: Medicinal products - authorisations, EMA; D6: Medicinal products -
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/813938/2011 Rev 3* Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies (Rev 3) Date for coming into effect of first version 2 July 2012
More informationThe EU Risk Management Plan - a tool to address the uncertainties at the time of approval, and manage the risks of medicines
The EU Risk Management Plan - a tool to address the uncertainties at the time of approval, and manage the risks of medicines Health care uncertainty assessment workshop Session 3: The challenges of health
More informationMonitoring safety of medicines for patients
Monitoring safety of medicines for patients Pharmacovigilance activities related to medicines for human use in the EU (COM(2016) 498) Health and Food Safety The information contained in this publication
More informationQuestions And Answers To Support The
Questions And Answers To Support The Implementation Of The Pharmacovigilance Legislation - Update This Question and answers section gives advice on regulatory issues in on the interpretation and implementation
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE
More informationUpdate on SCOPE - Strengthening Collaborations to. Operate Pharmacovigilance in Europe
Update on SCOPE - Strengthening Collaborations to Operate Pharmacovigilance in Europe Background Review Of The EU System 2 Pharmacovigilance Legislation 2012: EU Pharmacovigilance legislation Directive
More informationInterdependencies of Pharmacovigilance and Regulatory Affairs
Lorenz userbridge 2013 Budapest, September 17th Interdependencies of Pharmacovigilance and Regulatory Affairs Dr. rer. nat. Markus Dehnhardt Deputy QPPV Biologist Toxicologist Medical advisor Agenda 1.
More informationDoc. No. DPS/GDL/034 Revision No.: 0 Effective Date: 26 April 2018 Review-Due Date: 26 April 2021
National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda Tel: 256-0414 - 255665/347391/2 E-mail: ndaug@nda.or.ug Website: http://www.nda.or.ug Doc. No. DPS/GDL/034
More informationThe new Pharmacovigilance legislation and implementation planning
The new Pharmacovigilance legislation and implementation planning Second Stakeholders meeting 17 June 2011 European Medicines Agency, London, UK Presented by: Franck Diafouka Manager, Pharmacovigilance
More informationHow are medicines evaluated at the EMA
How are medicines evaluated at the EMA Presented by: Nathalie Bere Patient interaction / Stakeholders and communication Division An agency of the European Union The European System Centralised Procedure
More informationPHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use
PHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use This guideline replaces PHV-3 guideline version 3 effective from 11. 01. 2016 The guideline provides
More informationPeriod of time from September 2015 to August Summary of pharmacovigilance system audit report results v3
Report to the European Commission on Pharmacovigilance audits carried out in BASG/AGES (Austrian Federal Office for Safety in Health Care / Austrian Medicines and Medical Devices Agency), Austria Period
More informationRe: PCIM/11/01 Public Consultation on Implementing Measures for Pharmacovigilance
07 November 2011 By email: sanco pharmaceuticals@ec.europa.eu Directorate General for Health and Consumers Unit SANCO/D/3 BE 1049 Brussels Belgium Dear Sirs, Re: PCIM/11/01 Public Consultation on Implementing
More informationBrexit Guidance for Stakeholders Human and veterinary medicines
Brexit Guidance for Stakeholders Human and veterinary medicines DATE: 03 JANUARY 2018 V.2 This guide does not purport to be an interpretation of law and/or regulations. The content provided is subject
More informationSafety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington
Safety reporting requirements in the post marketing phase Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington DISCLAIMER These materials have been prepared solely for educational
More informationQuestions and answers on preparation, management and assessment of periodic safety update reports (PSURs)
21 June 2018 EMA/CVMP/PhVWP/126661/2009-Rev.4-corr. Committee for Medicinal Products for Veterinary Use Questions and answers on preparation, management and assessment of periodic safety update reports
More informationGood Pharmacovigilance Practice Tunisian guidelines
Good Pharmacovigilance Practice Tunisian guidelines Introduction Arab ministers of health came to a common decree (number 7) in their 37th regular meeting in March 2012. The Higher Technical Committee
More informationEudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia
EudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia Presented by: Vladimir Raketić, DVM, spec; Audit /QM group Ministry of Agriculture, Forestry and Water Managment, Veterinary
More informationAgenda item 4.1 Draft proposal - Notifications of the location of the Pharmacovigilance System Master File (PSMF)
EMA Implementation Working Group with EU Pharmaceutical Industry Associations on the implementation of Article 57(2), second subparagraph of Regulation (EC) 726/2004 Agenda item 4.1 Draft proposal - Notifications
More informationVM-ID: MU101_20_001e_WL - Wegleitung_HD - Hilfsdokument / V3.0 / dst / er / / 6
Contents 1 Abbreviations... 1 2 Requirements for signal reports... 2 3 Introduction... 2 4 Objective... 2 5 Scope... 2 6 Company signals (signals evaluated by the MAH)... 2 6.1 Signals involving a serious
More informationFOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE
FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE Document No. : Date of First Adoption : 1st February, 2013 Date of Issue : 1 st March, 2013 Version No. : 02 Revision 1 :
More informationPharmacovigilance Inspection Metrics Report
Pharmacovigilance Inspection Metrics Report April 2016 - March 2017 1. Introduction During the period 01 April 2016 to 31 March 2017, the GPvP Inspectorate conducted 36 inspections of marketing authorisation
More informationThe PRAC Roles and challenges Focus on RMPs and RMAs. Prof. Jean-Michel Dogné. Head of the Department of Pharmacy PRAC effective member
The PRAC Roles and challenges Focus on RMPs and RMAs Prof. Jean-Michel Dogné Head of the Department of Pharmacy PRAC effective member Rue de Bruxelles, 61 B-5000 Namur, Belgium Phone: 0032 (0)81 724289
More informationSPOR data management services - high level changes
6 July 2017 EMA/551661/2016 version 3 Information Management Division Table of contents 1. Introduction... 2 2. New solutions for access and use of SPOR data... 2 2.1. RMS backward compatibility... 2 2.2.
More information